New lung cancer drug adds nearly six months of survival; stomach cancer treatment doubles it

ynet (אנגלית) תרבות

Two Phase 3 trials presented at Europe's leading oncology conference show major survival gains: Roche's divarasib outperforms existing targeted lung cancer drugs, while AstraZeneca's experimental therapy doubles median survival for…